8/11/2014 8:28:11 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development of novel, proprietary therapeutics based on hypoxia-inducible factor (HIF) biology and the commercialization of these products for patients with kidney disease, today announced financial results for the second quarter ended June 30, 2014.
“Over the past few months, we have advanced our efforts to deliver a novel, best-in-class therapy that harnesses the power of HIF biology for the treatment of anemia secondary to chronic kidney disease, a significant and growing patient population that remains severely under-treated,” stated John P. Butler, President and Chief Executive Officer of Akebia. “We completed enrollment in the Phase 2b trial of AKB-6548, strengthened our board with two key additions, and expanded our management team to help drive growth and advance our programs. We look forward to reporting top-line clinical trial results from the Phase 2b study in the fourth quarter of this year.”
Help employers find you! Check out all the jobs and post your resume.
comments powered by